U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Infusion-Related Reaction

MedGen UID:
181762
•Concept ID:
C0948715
•
Pathologic Function
Synonym: Infusion Related Reaction

Definition

A reaction to the infusion of pharmacological or biological substances. Symptoms may appear within minutes to hours following the infusion and may include pruritus, flushing, swelling, dyspnea, bronchospasm, and hypotension. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVInfusion-Related Reaction

Professional guidelines

PubMed

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch RE, Cho BC
Lung Cancer 2023 Apr;178:166-171. Epub 2023 Feb 15 doi: 10.1016/j.lungcan.2023.02.008. PMID: 36868177
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C
Br J Haematol 2021 Mar;192(5):869-878. Epub 2020 Jul 30 doi: 10.1111/bjh.16980. PMID: 33216361
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
Cortes JE, de Lima M, Dombret H, Estey EH, Giralt SA, Montesinos P, Röllig C, Venditti A, Wang ES
J Hematol Oncol 2020 Oct 15;13(1):137. doi: 10.1186/s13045-020-00975-2. PMID: 33059764Free PMC Article

Recent clinical studies

Therapy

A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Frentzas S, Gan HK, Cosman R, Coward J, Tran B, Millward M, Zhou Y, Wang W, Xia D, Wang ZM, Li B, Xia M, Desai J
Cell Rep Med 2023 Nov 21;4(11):101242. Epub 2023 Oct 17 doi: 10.1016/j.xcrm.2023.101242. PMID: 37852261Free PMC Article
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X, Xu N, Li Z, Shen L, Ji K, Zheng Z, Liu D, Lou H, Bai L, Liu T, Li Y, Li Y, Fan Q, Feng M, Zhong H, Huang Y, Lou G, Wang J, Lin X, Chen Y, An R, Li C, Zhou Q, Huang X, Guo Z, Wang S, Li G, Fei J, Zhu L, Zhu H, Li X, Li F, Liao S, Min Q, Tang L, Shan F, Gong J, Gao Y, Zhou J, Lu Z, Li X, Li J, Ren H, Liu X, Yang H, Li W, Song W, Wang ZM, Li B, Xia M, Wu X, Ji J
Lancet Oncol 2023 Oct;24(10):1134-1146. doi: 10.1016/S1470-2045(23)00411-4. PMID: 37797632
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS
Lancet Haematol 2022 May;9(5):e327-e339. Epub 2022 Apr 1 doi: 10.1016/S2352-3026(22)00072-2. PMID: 35366963Free PMC Article
Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions.
Arastu AH, Elstrott BK, Martens KL, Cohen JL, Oakes MH, Rub ZT, Aslan JJ, DeLoughery TG, Shatzel J
JAMA Netw Open 2022 Mar 1;5(3):e224488. doi: 10.1001/jamanetworkopen.2022.4488. PMID: 35353168Free PMC Article
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J
Lancet Oncol 2019 Apr;20(4):518-530. Epub 2019 Mar 8 doi: 10.1016/S1470-2045(18)30904-5. PMID: 30857956Free PMC Article

Prognosis

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators
Lancet Oncol 2021 Nov;22(11):1530-1540. Epub 2021 Oct 14 doi: 10.1016/S1470-2045(21)00471-X. PMID: 34656227Free PMC Article
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C
Br J Haematol 2021 Mar;192(5):869-878. Epub 2020 Jul 30 doi: 10.1111/bjh.16980. PMID: 33216361
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R
Lancet Haematol 2019 Aug;6(8):e429-e437. Epub 2019 Jul 8 doi: 10.1016/S2352-3026(19)30089-4. PMID: 31296423
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J
Lancet Oncol 2019 Apr;20(4):518-530. Epub 2019 Mar 8 doi: 10.1016/S1470-2045(18)30904-5. PMID: 30857956Free PMC Article
Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.
Dawson K, Moran M, Guindon K, Wan H
Clin J Oncol Nurs 2016 Apr;20(2):E41-8. doi: 10.1188/16.CJON.E41-E48. PMID: 26991722

Clinical prediction guides

A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Frentzas S, Gan HK, Cosman R, Coward J, Tran B, Millward M, Zhou Y, Wang W, Xia D, Wang ZM, Li B, Xia M, Desai J
Cell Rep Med 2023 Nov 21;4(11):101242. Epub 2023 Oct 17 doi: 10.1016/j.xcrm.2023.101242. PMID: 37852261Free PMC Article
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD
Clin Cancer Res 2023 Jun 13;29(12):2210-2219. doi: 10.1158/1078-0432.CCR-22-3313. PMID: 37000164Free PMC Article
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch RE, Cho BC
Lung Cancer 2023 Apr;178:166-171. Epub 2023 Feb 15 doi: 10.1016/j.lungcan.2023.02.008. PMID: 36868177
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chávez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS
Lancet Haematol 2022 May;9(5):e327-e339. Epub 2022 Apr 1 doi: 10.1016/S2352-3026(22)00072-2. PMID: 35366963Free PMC Article
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J
Lancet Oncol 2019 Apr;20(4):518-530. Epub 2019 Mar 8 doi: 10.1016/S1470-2045(18)30904-5. PMID: 30857956Free PMC Article

Recent systematic reviews

Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review.
Ravi G, Eerike M, Konda VR, Bisoi D, Raj GM, Priyadarshini R, Mali KR, Chaliserry LF
Monoclon Antib Immunodiagn Immunother 2023 Apr;42(2):77-94. doi: 10.1089/mab.2022.0036. PMID: 37129306
Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis.
Yang L, Zheng Z, Li N, Zheng B, Liu M, Cai H
J Clin Pharm Ther 2022 Dec;47(12):1923-1931. Epub 2022 Nov 7 doi: 10.1111/jcpt.13799. PMID: 36345167
Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis.
Dubinsky S, Patel D, Wang X, Srikanthan A, Ng TL, Tsang C
Support Care Cancer 2022 Jul;30(7):5627-5644. Epub 2022 Feb 12 doi: 10.1007/s00520-022-06891-0. PMID: 35150312
Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials.
Cargnin S, Shin JI, Genazzani AA, Nottegar A, Terrazzino S
Cancer Chemother Pharmacol 2020 Nov;86(5):577-588. Epub 2020 Oct 1 doi: 10.1007/s00280-020-04156-3. PMID: 33005979
Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis.
Wu Y, Wang Y, Gu Y, Xia J, Kong X, Qian Q, Hong Y
Hematology 2017 Dec;22(10):578-584. Epub 2017 Jun 3 doi: 10.1080/10245332.2017.1333974. PMID: 28580841

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...